| Development Programs | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|---|
| VK2809 (TRβ Agonist) | NASH |
|
Phase 2b VOYAGE trial ongoing | |||
| VK2735 (Dual GLP-1/GIP agonist) | Metabolic disorders |
|
Phase 1 ongoing | |||
| VK0214 (TRβ Agonist) | X-ALD |
|
Phase 1b ongoing | |||
| Other Programs | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
| VK5211 (SARM) | Hip fracture, muscle wasting |
|
Phase 2 completed | |||
| VK0612 (FBPase inhibitor) | Type 2 Diabetes |
|
Phase 2a completed | |||
| VK1430 (DGAT-1 inhibitor) | Hypertriglyceridemia, NASH |
|
Preclinical | |||
| Product/Target | Indication | Phase |
|---|---|---|
| VK2809 (TRβ Agonist) | NASH | Phase 2 |
| VK2735 (Dual GLP-1/GIP agonist) | Metabolic disorders | Phase 1 |
| VK0214 (TRβ Agonist) | X_ALD | Phase 1 |
| VK5211 (SARM) | Hip fracture, muscle wasting | Phase 2 |
| VK0612 (FBPase inhibitor) | Hip fracture, muscle wasting | Phase 2 |
| VK1430 (DGAT-1 inhibitor) | Hypertriglyceridemia, NASH | Phase 1 |